Pan-Cancer Analysis Identified C1ORF112 as a Potential Biomarker for Multiple Tumor Types

Abstract

<i>C1ORF112</i> is an evolutionarily conserved gene across vertebrates. Over the last decade, studies have suggested that <i>C1ORF112</i> may play a role in tumorigenesis. Using The Cancer Genome Atlas datasets, we explored the role of <i>C1ORF112</i> across various tumor types in this study. In most tumor types, <i>C1ORF112</i> expression was increased in tumor tissues compared to corresponding non-tumor tissues. In patients with certain tumor types, higher <i>C1ORF112</i> expression was correlated with shorter overall survival, disease-free survival, and progression-free survival. Further analyses of <i>C1ORF112</i> genetic alteration data showed that <i>C1ORF112</i> amplification and mutations may have an impact on liver hepatocellular carcinoma and uterine corpus endometrial carcinoma prognosis. In cancers including lower grade glioma and adrenocortical carcinoma, <i>C1ORF112</i> expression was linked to cancer-associated fibroblast infiltration. Gene Ontology analysis showed that <i>C1ORF112</i> was co-expressed with genes involved in biological processes such as cell cycle and mitotic regulation. The protein interaction network demonstrated that <i>C1ORF112</i> physically interacted with <i>RAD51</i>, <i>DMC1</i>, and <i>FIGNL1</i>, which have well characterized functions in DNA repair and cell cycle regulation. This pan-cancer study revealed the prognostic value and oncogenic role of <i>C1ORF112</i> across multiple tumor types.